Skip to main content
UnicoCell logo

UnicoCell — Investor Relations & Filings

Ticker · 6794 ISIN · TW0006794001 TW Professional, scientific and technical activities
Open in API
Filings indexed 34 across all filing types
Latest filing 2026-04-08 Proxy Solicitation & In…
Country TW Taiwan
Listing TW 6794

About UnicoCell

https://www.unicocell.com

UnicoCell Biomed Co., Ltd. specializes in regenerative medicine, focusing on the research, development, and clinical application of stem cell technologies. The company’s operations are centered on three primary axes: the development of novel stem cell therapeutics, the production of stem cell-derived exosomes, and the provision of cell manufacturing and Contract Development and Manufacturing Organization (CDMO) services. Its lead candidate, ELIXCYTE, is an adipose-derived stem cell therapy undergoing Phase 3 clinical trials for indications such as knee osteoarthritis and chronic kidney disease. Additionally, the company maintains an allogeneic stem cell bank and provides autologous adipose-derived stem cell therapy services. Utilizing patented manufacturing processes and proprietary technology, UnicoCell offers integrated solutions from research to large-scale production to address unmet medical needs in the regenerative therapy sector.

Recent filings

Filing Released Lang Actions
公告本公司董事會決議召開115年股東常會(新增召集事由)
Proxy Solicitation & Information Statement Classification · 75% confidence The document is a formal announcement by the board of directors of the upcoming annual shareholders’ meeting (115th AGM), including meeting date, venue, detailed agenda items, electronic voting period, and proxy‐related instructions. It is not the full annual report or financial statements themselves but rather informational materials to solicit shareholder votes. This aligns with the Proxy Solicitation & Information Statement category (PSI).
2026-04-08 Chinese
公告董事會決議擬發行限制員工權利新股案
Share Issue/Capital Change Classification · 85% confidence The document is a regulatory disclosure to the Taiwan "公開資訊觀測站" detailing the board of directors’ resolution to issue new restricted employee shares, including issuance amount, vesting conditions, dilution impact, and accounting treatment. This is an announcement of a new share issuance/capital change, fitting the "Share Issue/Capital Change" category (Code: SHA).
2026-04-08 Chinese
115年03月內部人持股異動(事後)
Director's Dealing Classification · 90% confidence The document is a detailed table of insider (“內部人”) shareholdings and monthly changes for company directors, officers, and their related parties. It discloses personal share counts, increases, and decreases. This matches the definition of a Director’s Dealing (insider transactions) report. There is no broader financial discussion or earnings commentary, and the primary purpose is to report insiders’ share transactions. Therefore, this should be classified as DIRS.
2026-04-07 Chinese
115年03月董事會成員及持股
Director's Dealing Classification · 85% confidence The document is a disclosure of insider shareholdings (董事長、董事、獨立董事、總經理等內部人及其關係人目前持股及設質狀況), showing each director/executive’s share amounts and pledged shares. This aligns with reporting of personal share transactions or holdings by company directors and executives, fitting the “Director’s Dealing” (DIRS) category rather than an earnings release, report publication announcement, or share issue. Therefore, the filing type is DIRS.
2026-04-07 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.